These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21820475)

  • 1. A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1.
    Tetteh KK; Conway DJ
    Vaccine; 2011 Oct; 29(44):7811-7. PubMed ID: 21820475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
    Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
    Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extensive antigenic polymorphism within the repeat sequence of the Plasmodium falciparum merozoite surface protein 1 block 2 is incorporated in a minimal polyvalent immunogen.
    Tetteh KK; Cavanagh DR; Corran P; Musonda R; McBride JS; Conway DJ
    Infect Immun; 2005 Sep; 73(9):5928-35. PubMed ID: 16113313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
    Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
    Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.
    Singh S; Kennedy MC; Long CA; Saul AJ; Miller LH; Stowers AW
    Infect Immun; 2003 Dec; 71(12):6766-74. PubMed ID: 14638762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response.
    Cowan GJ; Creasey AM; Dhanasarnsombut K; Thomas AW; Remarque EJ; Cavanagh DR
    PLoS One; 2011; 6(10):e26616. PubMed ID: 22073118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
    Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
    Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria.
    Polley SD; Tetteh KK; Cavanagh DR; Pearce RJ; Lloyd JM; Bojang KA; Okenu DM; Greenwood BM; McBride JS; Conway DJ
    Infect Immun; 2003 Apr; 71(4):1833-42. PubMed ID: 12654798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
    de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL
    Malar J; 2011 Sep; 10():266. PubMed ID: 21920045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of deleting 9 amino acid residues at N-terminus on immunogenicity of a Plasmodium falciparum chimeric protein].
    Zhang QF; Pan WQ; Qu L; Xue XY
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Apr; 35(4):345-9. PubMed ID: 12673388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.
    Goodman AL; Epp C; Moss D; Holder AA; Wilson JM; Gao GP; Long CA; Remarque EJ; Thomas AW; Ammendola V; Colloca S; Dicks MD; Biswas S; Seibel D; van Duivenvoorde LM; Gilbert SC; Hill AV; Draper SJ
    Infect Immun; 2010 Nov; 78(11):4601-12. PubMed ID: 20713623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.
    Gupta PK; Mukherjee P; Dhawan S; Pandey AK; Mazumdar S; Gaur D; Jain SK; Chauhan VS
    Clin Vaccine Immunol; 2014 Jun; 21(6):886-97. PubMed ID: 24789797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human IgG subclass antibodies to the 19 kilodalton carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (MSP1(19)) and predominance of the MAD20 allelic type of MSP1 in Uganda.
    Apio B; Nalunkuma A; Okello D; Riley E; Egwang TG
    East Afr Med J; 2000 Apr; 77(4):189-93. PubMed ID: 12858901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of a vaccinia virus vectored multi-epitope live vaccine candidate for Plasmodium falciparum.
    Dong W; Li M; Bi H; Li Y; Wu J; Qu L
    Int J Parasitol; 2001 Jan; 31(1):57-62. PubMed ID: 11165271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2.
    Krishnarjuna B; Andrew D; MacRaild CA; Morales RA; Beeson JG; Anders RF; Richards JS; Norton RS
    Sci Rep; 2016 Feb; 6():20613. PubMed ID: 26865062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection.
    Polley SD; Tetteh KK; Lloyd JM; Akpogheneta OJ; Greenwood BM; Bojang KA; Conway DJ
    J Infect Dis; 2007 Jan; 195(2):279-87. PubMed ID: 17191173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
    Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
    Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shift in epitope dominance of IgM and IgG responses to Plasmodium falciparum MSP1 block 4.
    Chang SP; Kayatani AK; Terrientes ZI; Herrera S; Leke RG; Taylor DW
    Malar J; 2010 Jan; 9():14. PubMed ID: 20070906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits.
    Reed ZH; Kieny MP; Engers H; Friede M; Chang S; Longacre S; Malhotra P; Pan W; Long C
    Vaccine; 2009 Mar; 27(10):1651-60. PubMed ID: 19038302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.